Abstract
Natural products have been the mainstay of cancer chemotherapy for the past 30 years. However, the quickening pace of (aberrant) gene identification, and the new technologies of combinatorial chemistry and high-throughput screening, should provide access to a wide range of new, totally synthetic drugs. Will these new approaches sound the death knell for therapies based on natural products? In reality, natural products are likely to provide many of the lead structures, and these will be used as templates for the construction of novel compounds with enhanced biological properties.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
References
Pettit, G. R., Pierson, F. H. & Herald, C. L. Anticancer Drugs from Animals, Plants and Microorganisms (Wiley, New York, 1994).
Newman, D. J., Cragg, G. M. & Snader, K. M. The influence of natural products on drug discovery. Nat. Prod. Rep. 17, 215–234 (2000).
Zubrod, C. G. Origins and development of chemotherapy research at the National Cancer Institute. Cancer Treat. Rep. 68, 9–19 (1984).
Cragg, G. M. et al. in Human Medicinal Agents from Plants (eds Kinghorn, A. D. & Balandrin, M. F.) 80–95 (ACS, Washington, 1993).
Fahy, J. Modifications of the Vinca alkaloids have major implications for tubulin interacting activities. Curr Pharm Des 7, 1181–1197 (2001).
Hande, K. R. Etoposide: four decades of development of a topoisomerase II inhibitor. Eur. J. Cancer, 34, 1514–1521 (1998).
Goodman, J. & Walsh, V. The Story of Taxol (Cambridge Univ. Press, Cambridge, UK, 2001).
Gueritte-Voegelein, F. et al. Relationships between the structure of Taxol analogues and their antimitotic activity. J. Med. Chem. 34, 992–998 (1991).
Schiff, P. B., Fant, J. & Horwitz, S. Promotion of microtubule assembly in vitro by Taxol. Nature 277, 665–667 (1979).
Kingston, D. G. I. Taxol, a molecule for all seasons. Chem. Commun. 867–880 (2001).
Chesnoff, S. The use of Taxol as a trademark. Nature 374, 208 (1995).
Jonsson, E. et al. Differential activity of topotecan and irinotecan. Eur. J. Cancer 36, 2120–2127 (2000).
Chen, A. Y. & Liu, L. F. DNA topoisomerases: essential enzymes and lethal targets. Annu Rev Pharmacol Toxicol 34, 191–218 (1994).
Leitheiser, C. J., Rishel, M. J., Wu, X. & Hecht, S. M. Solid-phase synthesis of bleomycin group antibiotics. Elaboration of deglycobleomycin A (5). Org. Lett. 2, 3397–3399 (2000).
Hofle, G. et al. Structure ekucidation of epothilones. Angew. Chemie 35, 1567–1569 (1996).
Nicolaou, K. C., Roschangar, F. & Vourloumis, D. Chemical biology of epothilones. Angew. Chemie 37, 2014–2045 (1998).
Nicolaou, K. C., Ritzen, A. & Namoto, K. Recent developments in the chemistry, biology and medicine of the epothilones. Chem. Commun. 1523–1535 (2001).
Nicolaou, K. C. et al. Designed epothilones: combinatorial synthesis, tubulin assembly properties, and cytotoxic action against Taxol-resistant tumour cells. Angew. Chemie 36, 2097–2100 (1997).
Danishefsky, S. J. et al. On the interactivity of complex synthesis and tumor pharmacology in the drug discovery process (epothilone analogues). J. Org. Chem. 66, 4369–4378 (2001).
Faulkner, D. J. Highllights of marine natural products chemistry (1972–1999). Nat. Prod. Rep. 17, 1–6 (2000).
Faulkner, D. J. Marine natural products. Nat Prod Rep 18, 1–49 (2001).
Nuijen, B. et al. Pharmaceutical developments of anticancer agents derived from marine sources. Anti-Cancer Drugs 11, 793–811 (2000).
Mendola, D. in Drugs from the Sea (ed. N. Fusetani) 121–133 (Karger, Basel, 2000).
Watson, C. Polymer-supported synthesis of non-oligomeric natural products. Angew. Chemie 38, 1903–1908 (1999).
Terrett, N. K., Gardner, M., Gordon, D. W., Kobylecki, R. J. & Steele, J. Combinatorial synthesis: the design of compound libraries and their application to drug discovery. Tetrahedron 51, 8135–8173 (1995).
Mutter, R. & Wills, M. Chemistry and biology of the bryostatins. Bioorg. Med. Chem. 8, 1841–1860 (2000).
Wender, P. A. et al. The design, computer modeling, solution structure, and biological evaluation of synthetic analogues of bryostatin 1. Proc. Natl Acad. Sci. USA 95, 6624–6629 (1998).
Wender, P. A. & Lippa, B. Synthesis and biological evaluation of bryostatin anaologues. Tet. Lett. 41, 1007–1011 (2000).
D'Ambrosio, M., Guerriero, A. & Pietra, F. Sarcodictyin. Helv. Chim. Acta 70, 2019 (1987).
Fenical, W. et al. Eleutherobin. J. Am. Chem. Soc. 119, 8744–8745 (1997).
Nicolaou, K. C. et al. Total synthesis of eleutherobin. Angew. Chemie 36, 2520–2524 (1997).
Danishefsky, S. J. et al. The total synthesis of eleutherobin. Angew. Chemie 37, 185–187, 789–791 (1998).
Nicolaou, K. C. et al. Solid and solution phase synthesis and biological evaluation of combinatorial sarcodictyin libraries. J. Am. Chem. Soc. 120, 10814–10826 (1998).
Kohler, G. & Milstein, C. Contimous cultures of fused cells secreting antibody of prediefined specificity. Nature 256, 495–497 (1975).
Niculescu-Duvaz, I. & Springer, C. J. Antibody-driected enzyme prodrug therapy (ADEPT). Adv Drug Deliv Rev 26, 151–172 (1997).
Smyth, T. P., O'Donnell, M. E., O'Connor, M. J. & St Ledger, J. O. β-lactamase-dependent prodrugs- recent developments. Tetrahedron 56, 5699–5707 (2000).
Bross, P. F. et al. Approval summary: gemtuzumab ozogamicin (Mylotarg) in relapsed acute myeloid leukemia. Clin. Cancer Res. 7, 1490–1496 (2001).
Langer, M., Kratz, F., Rothen-Rutishauser, B., Wunderli-Allenspach, H. & Beck-Sickinger, A. G. Novel peptide conjugates for tumor-specific chemotherapy. J. Med. Chem. 44, 1341–1348 (2001).
Corey, E. J., Gin, D. Y. & Kania, R. S. Enantioselective total synthesis of exteinascidin 743. J. Am. Chem. Soc. 118, 9202–9203 (1996).
Liekens, S., De Clercq, E. & Neyts, J. Angiogenesis: regulators and clinical applications. Biochem. Pharmacol. 61, 253–270 (2001).
Folkman, J. et al. Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumour growth. Nature 348, 555–557 (1990).
Wernert, N. et al. Inhibition of Ets-1 transcription factor expression by the antibiotic fumagillin. Angew. Chemie 38, 3228–3231 (1999).
Pettit, G. R. et al. Isolation and structure of the strong cell-growth and tubulin inhibitor combretastatin A4. Experientia 45, 209–211 (1989).
Griggs, J., Metcalfe, J. C. & Hesketh, R. Targeting tumour vasculature: the development of combretastatin A4. Lancet Oncol. 2, 82–87 (2001).
Grosios, K., Loadman, P. M., Swaine, D. J., Pettit, G. R. & Bibby, M. C. Combination chemotherapy with combretastatin A-4 phosphate and 5-fluorouracil in an experimental murine colon adenocarcinoma. Anticancer Res. 20, 229–233 (2000).
Weinstein-Oppenheimer, C. R., Blalock, W. L., Steelman, L. S., Chang, F. & McCubrey, J. A. The Raf signal transduction cascade as a target for chemotherapeutic intervention in growth factor-responsive tumors. Pharmacol. Ther. 88, 229–279 (2000).
Sano, M. Radicicol and geldanamycin prevent neurotoxic effects of anti-cancer drugs. Neuropharmacology 40, 947–953 (2001).
Cushman, M. et al. Design, synthesis, and biological evaluation of a series of lavendustin A analogues that inhibit EGRF and Syk tyrosine kinases, as well as tubulin polymerisation. J. Med. Chem. 44, 441–452 (2001).
Fabbro, D. et al. Inhibitors of protein kinases: CGP 41251, a protein kinase inhibitor with potential as an anticancer agent. Pharmacol. Ther. 82, 293–301 (1999).
Mann, J. et al. A novel inhibitor of human telomerase derived from 10H-indolo[3,2-b]quinoline. Bioorg. Med. Chem. Lett. 10, 2063–2066 (2000).
Autexier, C. Telomerase as a possible target for anticancer therapy. Chem. Biol. 6, R299–R303 (1999).
Author information
Authors and Affiliations
Related links
Related links
DATABASES
Rights and permissions
About this article
Cite this article
Mann, J. Natural products in cancer chemotherapy: past, present and future. Nat Rev Cancer 2, 143–148 (2002). https://doi.org/10.1038/nrc723
Issue Date:
DOI: https://doi.org/10.1038/nrc723
This article is cited by
-
OST-01, a natural product from Baccharis coridifolia, targets c-Myc-dependent ribogenesis in acute myeloid leukemia
Leukemia (2024)
-
The potential effect and mechanism of Saikosaponin A against gastric cancer
BMC Complementary Medicine and Therapies (2023)
-
Prostate Cancer, Oxidative Stress, and Antioxidant Phytochemicals: A Brief Review
Current Pharmacology Reports (2023)
-
Himalayan flora: targeting various molecular pathways in lung cancer
Medical Oncology (2023)
-
In Vitro Evaluation of Antioxidant, Antimicrobial, Cytotoxic, Anti-Inflammatory, Anti-Aging, Enzyme Inhibition Potential, and HPLC Analysis of Traditionally Used Plant Delphinium Uncinatum Wall
Pharmaceutical Chemistry Journal (2023)